With the benefit of hindsight, it makes the further Leiden testing look like a misstep IMO. The small molecule screening at WEHI Prof. Doherty refers to in his excellent article has been completed for MPL with "remarkable" results. I'm keen for management to explain why the next step wasn't a Phase 1/2. As we've discussed, not even a trial design registered or HREC application on foot.
Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-118
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |